Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
作者： Simon Linder , Henk G van der Poel , Andries M Bergman , Wilbert Zwart , Stefan Prekovic
DOI: 10.1530/ERC-18-0289
关键词:
摘要: The androgen receptor drives the growth of metastatic castration-resistant prostate cancer. This has led to development multiple novel drugs targeting this hormone-regulated transcription factor, such as enzalutamide – a potent antagonist. Despite plethora possible treatment options, absolute survival benefit each separately is limited few months. Therefore, current research efforts are directed determine optimal sequence therapies, discover effective in cancer and define patient subpopulations that ultimately from these treatments. Molecular studies provide evidence on which pathways mediate resistance may lead improved for review provides, firstly concise overview clinical development, use effectiveness advanced cancer, secondly it describes translational addressing response vs lastly highlights potential strategies enzalutamide-resistant setting.
bioscientifica.com
narcis.nl参考文章(206)
Agus Rizal AH Hamid, Minja J Pfeiffer, Gerald W Verhaegh, Ewout Schaafsma, Andre Brandt, Fred CGJ Sweep, John PM Sedelaar, Jack A Schalken, None, Aldo-keto Reductase Family 1 Member C3 (AKR1C3) Is a Biomarker and Therapeutic Target for Castration-Resistant Prostate Cancer Molecular Medicine. ,vol. 18, pp. 1449- 1455 ,(2012) , 10.2119/MOLMED.2012.00296
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard, Himisha Beltran, Wassim Abida, Robert K Bradley, Jake Vinson, Xuhong Cao, Pankaj Vats, Lakshmi P Kunju, Maha Hussain, Felix Y Feng, Scott A Tomlins, Kathleen A Cooney, David C Smith, Christine Brennan, Javed Siddiqui, Rohit Mehra, Yu Chen, Dana E Rathkopf, Michael J Morris, Stephen B Solomon, Jeremy C Durack, Victor E Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T Lis, Michaela Bowden, Stephen P Balk, Glenn Gaviola, Carrie Sougnez, Manaswi Gupta, Y Yu Evan, Elahe A Mostaghel, Heather H Cheng, Hyojeong Mulcahy, Lawrence D True, Stephen R Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquin Mateo, Raquel Perez-Lopez, Francesca Demichelis, Brian D Robinson, Marc Schiffman, David M Nanus, Scott T Tagawa, Alexandros Sigaras, Kenneth W Eng, Olivier Elemento, Andrea Sboner, Elisabeth I Heath, Howard I Scher, Kenneth J Pienta, Philip Kantoff, Johann S De Bono, Mark A Rubin, Peter S Nelson, Levi A Garraway, Charles L Sawyers, Arul M Chinnaiyan, None, Integrative clinical genomics of advanced prostate cancer Cell. ,vol. 161, pp. 1215- 1228 ,(2015) , 10.1016/J.CELL.2015.05.001
Zhenfei Li, Andrew C. Bishop, Mohammad Alyamani, Jorge A. Garcia, Robert Dreicer, Dustin Bunch, Jiayan Liu, Sunil K. Upadhyay, Richard J. Auchus, Nima Sharifi, Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer Nature. ,vol. 523, pp. 347- 351 ,(2015) , 10.1038/NATURE14406
M Hussain, M Wolf, E Marshall, E D Crawford, M Eisenberger, Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. Journal of Clinical Oncology. ,vol. 12, pp. 1868- 1875 ,(1994) , 10.1200/JCO.1994.12.9.1868
Emmanuel S. Antonarakis, Enzalutamide: the emperor of all anti-androgens Translational Andrology and Urology. ,vol. 2, pp. 119- 120 ,(2013) , 10.3978/J.ISSN.2223-4683.2012.09.04
C D Taylor, P Elson, D L Trump, Importance of continued testicular suppression in hormone-refractory prostate cancer. Journal of Clinical Oncology. ,vol. 11, pp. 2167- 2172 ,(1993) , 10.1200/JCO.1993.11.11.2167
I F Tannock, D Osoba, M R Stockler, D S Ernst, A J Neville, M J Moore, G R Armitage, J J Wilson, P M Venner, C M Coppin, K C Murphy, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of Clinical Oncology. ,vol. 14, pp. 1756- 1764 ,(1996) , 10.1200/JCO.1996.14.6.1756
Øystein Fodstad, Knut Breistøl, Øyvind S. Bruland, Roy H. Larsen, Gjermund Henriksen, Significant Antitumor Effect from Bone-seeking, α-Particle-emitting 223Ra Demonstrated in an Experimental Skeletal Metastases Model Cancer Research. ,vol. 62, pp. 3120- 3125 ,(2002)
Hai-Jun Zhou, Jun Yan, Weiping Luo, Gustavo Ayala, Sue-Hwa Lin, Halime Erdem, Michael Ittmann, Sophia Y. Tsai, Ming-Jer Tsai, SRC-3 Is Required for Prostate Cancer Cell Proliferation and Survival Cancer Research. ,vol. 65, pp. 7976- 7983 ,(2005) , 10.1158/0008-5472.CAN-04-4076
T.M. Beer, W.C. Pierce, B.A. Lowe, W.D. Henner, Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer Annals of Oncology. ,vol. 12, pp. 1273- 1279 ,(2001) , 10.1023/A:1012258723075